News & stories

News | Mar 17, 2022

MSF responds to potential compromise on the TRIPS waiver

News | Feb 22, 2022

MSF: No time to lose on landmark TRIPS waiver

News | Jan 31, 2022

The Biden administration must disclose the costs of clinical trials

Forcing pharmaceutical corporations to share the costs of all clinical trials could play a key role in expanding access to medicines everywhere

News | Dec 16, 2021

Letter to US government on its responsibility to help scale up the supply of COVID-19 vaccines

US should immediately demand pharmaceutical corporations transfer mRNA vaccine technology as new report identifies more than 100 possible additional manufacturers

News | Nov 29, 2021

MSF: TRIPS waiver must be urgently adopted despite WTO Ministerial Conference postponement

News | Nov 16, 2021

MSF responds to Pfizer and Medicines Patent Pool license for new COVID-19 treatment

News | Oct 27, 2021

MSF: Merck and Medicines Patent Pool license for new COVID-19 drug molnupiravir doesn’t go far eno

News | Oct 12, 2021

South Africa protests urge US and EU to move forward on TRIPS waiver for COVID-19 vaccines and medical tools

MSF joins activists pushing to break the stalemate ahead of critical WTO meeting this week

News | Oct 11, 2021

MSF responds to Merck’s filing for FDA emergency use authorization for COVID-19 drug

If approved, first COVID-19 antiviral pill molnupiravir could have big impact. But it will need to be made available and affordable for people everywhere.

News | Oct 11, 2021

US must stop hoarding excess COVID-19 vaccine doses